PARSIPPANY, N.J., April 17, 2024 — Zoetis announced today it has received an expanded label approval from the Food and Drug Administration’s Center for Veterinary Medicine (CVM) for Synovex Choice® to increase rate of weight gain in growing beef steers or heifers in the dry lot production phase. Also approved is a new implant from Zoetis, Synovex® Primer™ that will be available for the dry lot market later in 2024.
“This approval provides beef producers with dry lot operations another tool to help them meet their production and profitability goals,” said John Hallberg, DVM, PhD, U.S. director of regulatory affairs, Zoetis. “As the first trenbolone acetate (TBA) implants approved for dry lot production, steers and heifers have the opportunity to gain additional weight with the appropriate nutritional inputs.”
Effective immediately, existing packages of Synovex Choice can be used in the dry lot production phase. Animal health product suppliers and cattle producers will begin seeing packaging for Synovex Choice with the updated indications by the end of 2024.
“This provides an opportunity for cattle producers with dry lot operations to incorporate a TBA implant in their program to help the cattle grow frame and put on lean muscle,” said Bryan Bernhard, PhD, nutritionist with Zoetis beef strategic technical services. “Dry lot operations have two main goals: get cattle healthy and get cattle growing. By adding Synovex Choice in the dry lot phase, cattle can gain more pounds before they go to the next phase, whether it is grazing or confined feeding.”
For more information on how the expanded label could fit your operation, please visit with your Zoetis sales representative. You also can visit www.Synovex.com to learn more.
Refer to individual labels for complete directions for use, precautions, and warnings. Reimplant only if and as directed in labeling.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.
